Sphingosine kinase, sphingosine-1-phosphate, and apoptosis - PubMed (original) (raw)
Review
Sphingosine kinase, sphingosine-1-phosphate, and apoptosis
Michael Maceyka et al. Biochim Biophys Acta. 2002.
Abstract
The sphingolipid metabolites ceramide (Cer), sphingosine (Sph), and sphingosine-1-phosphate (S1P) play an important role in the regulation of cell proliferation, survival, and cell death. Cer and Sph usually inhibit proliferation and promote apoptosis, while the further metabolite S1P stimulates growth and suppresses apoptosis. Because these metabolites are interconvertible, it has been proposed that it is not the absolute amounts of these metabolites but rather their relative levels that determines cell fate. The relevance of this "sphingolipid rheostat" and its role in regulating cell fate has been borne out by work in many labs using many different cell types and experimental manipulations. A central finding of these studies is that Sph kinase (SphK), the enzyme that phosphorylates Sph to form S1P, is a critical regulator of the sphingolipid rheostat, as it not only produces the pro-growth, anti-apoptotic messenger S1P, but also decreases levels of pro-apoptotic Cer and Sph. Given the role of the sphingolipid rheostat in regulating growth and apoptosis, it is not surprising that sphingolipid metabolism is often found to be disregulated in cancer, a disease characterized by enhanced cell growth, diminished cell death, or both. Anticancer therapeutics targeting SphK are potentially clinically relevant. Indeed, inhibition of SphK has been shown to suppress gastric tumor growth [Cancer Res. 51 (1991) 1613] and conversely, overexpression of SphK increases tumorigenicity [Curr. Biol. 10 (2000) 1527]. Moreover, S1P has also been shown to regulate angiogenesis, or new blood vessel formation [Cell 99 (1999) 301], which is critical for tumor progression. Furthermore, there is intriguing new evidence that S1P can act in an autocrine and/or paracrine fashion [Science 291 (2001) 1800] to regulate blood vessel formation [J. Clin. Invest. 106 (2000) 951]. Thus, SphK may not only protect tumors from apoptosis, it may also increase their vascularization, further enhancing growth. The cytoprotective effects of SphK/S1P may also be important for clinical benefit, as S1P has been shown to protect oocytes from radiation-induced cell death in vivo [Nat. Med. 6 (2000) 1109]. Here we review the growing literature on the regulation of SphK and the role of SphK and its product, S1P, in apoptosis.
Similar articles
- Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases.
Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Hait NC, et al. Biochim Biophys Acta. 2006 Dec;1758(12):2016-26. doi: 10.1016/j.bbamem.2006.08.007. Epub 2006 Aug 18. Biochim Biophys Acta. 2006. PMID: 16996023 Review. - Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.
Kawabori M, Kacimi R, Karliner JS, Yenari MA. Kawabori M, et al. World J Cardiol. 2013 Apr 26;5(4):75-86. doi: 10.4330/wjc.v5.i4.75. World J Cardiol. 2013. PMID: 23675553 Free PMC article. - [Sphingosine kinase 1 and tumor].
Zhang CX, He HW, Shao RG. Zhang CX, et al. Yao Xue Xue Bao. 2013 Jul;48(7):971-8. Yao Xue Xue Bao. 2013. PMID: 24133963 Review. Chinese. - Sphingosine kinase activity is required for sphingosine-mediated phospholipase D activation in C2C12 myoblasts.
Meacci E, Cencetti F, Donati C, Nuti F, Becciolini L, Bruni P. Meacci E, et al. Biochem J. 2004 Aug 1;381(Pt 3):655-63. doi: 10.1042/BJ20031636. Biochem J. 2004. PMID: 15109308 Free PMC article. - Sphingosine kinase signalling in immune cells.
Kee TH, Vit P, Melendez AJ. Kee TH, et al. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):153-61. doi: 10.1111/j.1440-1681.2005.04166.x. Clin Exp Pharmacol Physiol. 2005. PMID: 15743396 Review.
Cited by
- Effects of the S1P/S1PR1 Signaling Pathway on High Glucose-Induced NRK-52E Epithelial-Mesenchymal Transition Via Regulation of ROS/NLRP3.
Tian J, Chen J, Sun Q, Huang T, Xu H, Wang J, Ma Z. Tian J, et al. Inflammation. 2024 Aug 7. doi: 10.1007/s10753-024-02118-y. Online ahead of print. Inflammation. 2024. PMID: 39110363 - New insights into the antibiofilm activity and mechanism of Mannosylerythritol Lipid-A against Listeria monocytogenes EGD-e.
Liu X, Liu S, Wang Y, Shi Y, Chen Q. Liu X, et al. Biofilm. 2024 May 11;7:100201. doi: 10.1016/j.bioflm.2024.100201. eCollection 2024 Jun. Biofilm. 2024. PMID: 38779407 Free PMC article. - Alzheimer's disease manifests abnormal sphingolipid metabolism.
Uranbileg B, Isago H, Sakai E, Kubota M, Saito Y, Kurano M. Uranbileg B, et al. Front Aging Neurosci. 2024 May 7;16:1368839. doi: 10.3389/fnagi.2024.1368839. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38774265 Free PMC article. - Inhibition of CERS1 in skeletal muscle exacerbates age-related muscle dysfunction.
Wohlwend M, Laurila PP, Goeminne LJE, Lima T, Daskalaki I, Li X, von Alvensleben G, Crisol B, Mangione R, Gallart-Ayala H, Lalou A, Burri O, Butler S, Morris J, Turner N, Ivanisevic J, Auwerx J. Wohlwend M, et al. Elife. 2024 Mar 20;12:RP90522. doi: 10.7554/eLife.90522. Elife. 2024. PMID: 38506902 Free PMC article. - Sphingolipid biosynthetic inhibitor L-Cycloserine prevents oxidative-stress-mediated death in an in vitro model of photoreceptor-derived 661W cells.
Tahia F, Basu SK, Prislovsky A, Mondal K, Ma D, Kochat H, Brown K, Stephenson DJ, Chalfant CE, Mandal N. Tahia F, et al. Exp Eye Res. 2024 May;242:109852. doi: 10.1016/j.exer.2024.109852. Epub 2024 Mar 8. Exp Eye Res. 2024. PMID: 38460719
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources